Penumbra, Inc. Stock News

Penumbra's AI-guided aspiration system and scalable platform uniquely position it as a leader in stroke and PE intervention, justifying a Buy rating. First-mover advantage in intelligent thrombectomy, expanding European reimbursement, and an aging population create strong long-term growth tailwinds. Despite premium valuation multiples, PEN's innovation, ecosystem, and divestiture of non-core as...

STORM-PE is a first-of-its-kind clinical trial comparing computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ with anticoagulation versus anticoagulation alone in the treatment of acute intermediate-high risk pulmonary embolism ALAMEDA, Calif. , June 16, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the completion...

ALAMEDA, Calif. , June 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and softest coil on the marketi.

ALAMEDA, Calif. , May 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below.

While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology sector mid-cap stocks have stood out for their resilience and outperformance.

ALAMEDA, Calif. , April 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025.

Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetr...

Penumbra, Inc. (NYSE:PEN ) Q1 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Cecilia Furlong - Business Development & IR Adam Elsesser - Chairman & CEO Maggie Yuen - CFO Jason Mills - EVP, Strategy Conference Call Participants Robbie Marcus - JPMorgan Lei Huang - Wells Fargo Pito Chickering - Deutsche Bank Macauley Kilbane - William Blair Bill Plovanic - Canaccord ...